{"entity":{"id":"inv-9956","kind":"drug","name":"INV-9956","aka":[],"tldr":"INV-9956 is an experimental CYP11A1 inhibitor from Shenzhen Ionova Life Sciences, in phase 2 trials for metastatic castration-resistant prostate cancer.","summary":"INV-9956 is a CYP11A1 inhibitor from Shenzhen Ionova Life Sciences. A CYP11A1 inhibitor for castration-resistant prostate cancer, given with dexamethasone and fludrocortisone acetate in the trial. Its furthest stage is phase 2, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. Company announced first patient dosed in the phase II trial (news dated 2025-12-05); FDA Fast Track for advanced mCRPC (news dated 2025-11-03). Registry trial is phase 1/2, recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Shenzhen Ionova Life Sciences: ionovabio.com","url":"https://www.ionovabio.com/en/companynews"},{"label":"Shenzhen Ionova Life Sciences: ionovabio.com","url":"https://www.ionovabio.com/en/companynews"},{"label":"Shenzhen Ionova Life Sciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06609005"},{"label":"ClinicalTrials.gov: trials of INV-9956","url":"https://clinicaltrials.gov/search?intr=INV-9956"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":["cyp11a1"],"drugs":[],"companies":["shenzhen-ionova-life-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06609005"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"INV-9956","modality":"CYP11A1 inhibitor","mechanism":"A CYP11A1 inhibitor for castration-resistant prostate cancer, given with dexamethasone and fludrocortisone acetate in the trial.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/inv-9956/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"target":[{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/"}],"company":[{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/"}],"trial":[{"id":"nct06609005","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06609005/"}]}}